DalsnaFinance › IPOs › Hemab Therapeutics Holdings › IPO
Hemab Therapeutics Holdings, Inc. completed its initial public offering on NASDAQ on May 1, 2026, pricing at $18.00 a share.
| Ticker | COAG |
|---|---|
| Exchange | NASDAQ |
| Status | Completed |
| Listing date | May 1, 2026 |
| Offering price | $18.00 |
| Shares offered | 16,750,000 |
| Total raised | $302M |
Hemab Therapeutics Holdings, Inc. sold 16,750,000 shares at $18.00 each on NASDAQ. Multiplied out, that is $301.5 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $302 million total recorded for the deal.
Measured by money raised, Hemab Therapeutics Holdings, Inc. was the 87th largest of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. The median deal in the same window raised $200 million, so this one was about 1.5 times the typical size.
Among the 342 listings on NASDAQ alone, it is the 46th largest.
May 2026 saw 28 completed IPOs in the site's data; by amount raised, Hemab Therapeutics Holdings, Inc. was the 7th largest of the 21 deals with a recorded size.
Its $18.00 offer price was tied for the 82nd highest (level with 12 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Hemab Therapeutics Holdings, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Hemab Therapeutics Holdings, Inc.. This page is general information, not investment advice.